

## Executive Summary Board of Directors Meeting January 29-30, 2015

### Proceedings:

- *Meeting Called to Order* at 8:00 a.m. (local time) on January 29 by Chair, Dr. John Wingard. A quorum was noted.
- *Minutes* from the September 18-19, 2014, Board meeting were reviewed and approved with no changes.
- *Update from CEO*  
It was stated that access to coverage and reimbursement remain a concern for the Medicare population. Meetings have been attended to explore coverage for other indications requiring transplant as well as to express the need for CMS coverage of search and procurement costs. On January 22, a Congressional Caucus to Cure Blood Cancers and Other Blood Disorders was held to educate members of congress about cellular transplantation.
- *YTD Results*  
To date, NMDP transplants facilitated were above forecast. Cord blood showed a decline.
- *Chief Financial Officer Report*  
A financial information update was provided December. Both domestic and international transplants, as well as procurements were above budget.
- *Audit*  
The Independent Auditor's report was presented to the board. With no questions, a motion was made, seconded and passed to approve the audit. Internal auditor activities for 2014 were reviewed.
- *New Technologies and Opportunities Advisory Group*  
The New Technologies and Opportunities Advisory Group conducted a meeting in December. Agenda items included environmental assessment information regarding cellular therapies, legal and ethical issues concerning use of adult donors for research and commercialization, and next steps for potential involvement in cellular therapies business. The group provided their recommendations to the board for next steps.
- *Registry Member and Donor Survey*  
Six focus groups were established at the Executive Committee's recommendation to get an understanding of how donors would react to using their donated cells in other ways. There were 34 donors and 23 registry members that participated and provided their feedback. Dr. Confer addressed concerns and questions of the focus groups and provided recommendations for moving forward.
- *Improving the Member Experience*  
This project focused on registry member experiences by way of interviews and reviewing previous research reports. The findings will be beneficial in determining how best to recruit and maintain members and providing them a positive experience. One of the biggest learnings of the project was the number of those who join the registry with no intention to donate.
- *Captive Insurance*  
WILLIS company performed a feasibility study for donor insurance. Staff from WILLIS presented the results to the board along with a captive project timeline. A resolution was proposed to the board for their approval securing Captive as the insurance organization.
- *Haploidentical Transplant update*  
An update was provided regarding the use of haploidentical transplants. Cost is lower and a BMT CTN study shows similar outcomes to a double cord transplant.
- *Strategic Planning*  
An update was provided regarding the 2014 strategic planning process, which is a 3-year plan including FY2016. Focus areas and cord blood task force recommendations were presented and reviewed.

- *IT Update*

An IT system update was provided along with required items that would need to be achieved to reach top performance and deliver business value.

- *Board Development Committee*

Four board members will roll off on September 30 due to term fulfillment. The board was asked to assist in identifying quality candidates for FY2016. Qualified candidates will have governance experience; support of this mission or this type of mission.

- *Time to Transplant*

NMDP set performance goals for network centers to speed up and streamline the process from diagnosis to transplant. NMDP and CIBMTR did a study to determine time to transplant. A dramatic time reduction was noted with increased assistance in certain areas from NMDP. Further research into assisting the transplant center processes will be reviewed.

- *Reauthorization – September 2015*

NMDP will seek reauthorization for the C.W. Bill Young Cell Transplantation Program. Lead sponsors are Senators Hatch and Reid as well as House Representatives Matsui, Smith, and Jolly. A *Congressional Caucus to Cure Blood Cancer and Other Blood Disorders* has been formed and an update will be provided at the June board meeting after the briefing on January 22, 2015.

- *Next meeting: Thursday & Friday, June 4-5, 2015 – Denver CO*

- *Meeting Adjourned*